The B7 Family Molecules in Oral Squamous Cell Carcinoma: a Systematic Review. Part I: B7-H1 (PD-L1) and B7-DC (PD-L2)

Overview

Journal Postepy Dermatol Alergol

Publisher Termedia

Specialty Allergy & Immunology

Date 2022 Jun 1

PMID 35645666

Authors

Anna Starzynska

Aleksandra Sejda

Lukasz Adamski

Paulina Adamska

Rafal Peksa

Monika Sakowicz-Burkiewicz

Piotr Wychowanski

Barbara A Jereczek-Fossa

Affiliations

Soon will be listed here.

Abstract

Introduction: Oral squamous cell carcinoma (OSCC) is the most common cancerous lesion in the oral cavity. During recent years, no significant reduction in the survival rate has been observed.

Aim: To systematically review the literature and to summarise correlations between B7 family proteins and prognosis in OSCC.

Material And Methods: A systematic review of the literature about B7-H1 (PD-L1) and B7-DC (PD-L2) was carried out, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Thirty-six articles published before 22 May 2020 were included in the systematic review.

Results: The biggest study group consisted of 305 patients and the smallest - 10 patients. PD-L1 proved to be a prognostic factor in patients with OSCC. Immunohistochemistry was the most commonly used diagnostic method.

Conclusions: Any mutations in the gene encoding PD-L1 and quantitative or functional changes in the status of PD-L1 may be important in the prognosis of OSCC.

Citing Articles

Verification of the expression trend and interaction prediction of innate immune cells and immune-checkpoint molecules in the process of oral mucosal carcinogenesis.

Li K, Shi L, Liu L, Wang J, Nie M, Liu X Hua Xi Kou Qiang Yi Xue Za Zhi. 2024; 42(2):192-206.

PMID: 38597079 PMC: 11034413. DOI: 10.7518/hxkq.2024.2023280.

High PD-L1 Expression on Tumor Cells Indicates Worse Overall Survival in Advanced Oral Squamous Cell Carcinomas of the Tongue and the Floor of the Mouth but Not in Other Oral Compartments.

Adamski L, Starzynska A, Adamska P, Kunc M, Sakowicz-Burkiewicz M, Marvaso G Biomedicines. 2021; 9(9).

PMID: 34572318 PMC: 8471659. DOI: 10.3390/biomedicines9091132.

References

Ko J, Gastman B, Conic R, Tellez Diaz Trujillo A, Diaz-Montero C, Billings S . Decreased T-Cell Programmed Death Receptor-1 Expression in Pregnancy-Associated Melanoma. Am J Dermatopathol. 2018; 41(3):180-187. DOI: 10.1097/DAD.0000000000001286. View

Swanson M, Sinha U . Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer—review of current data. Oral Oncol. 2014; 51(1):12-5. DOI: 10.1016/j.oraloncology.2014.10.010. View

Satgunaseelan L, Gupta R, Madore J, Chia N, Lum T, Palme C . Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype. Pathology. 2016; 48(6):574-80. DOI: 10.1016/j.pathol.2016.07.003. View

Maruse Y, Kawano S, Jinno T, Matsubara R, Goto Y, Kaneko N . Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2018; 47(7):836-845. DOI: 10.1016/j.ijom.2018.01.004. View

Stasikowska-Kanicka O, Wagrowska-Danilewicz M, Danilewicz M . CD8+ and CD163+ infiltrating cells and PD-L1 immunoexpression in oral leukoplakia and oral carcinoma. APMIS. 2018; 126(9):732-738. DOI: 10.1111/apm.12881. View

Troeltzsch M, Woodlock T, Pianka A, Otto S, Troeltzsch M, Ehrenfeld M . Is There Evidence for the Presence and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an Immunohistochemical Study. J Oral Maxillofac Surg. 2016; 75(5):969-977. DOI: 10.1016/j.joms.2016.11.006. View

Xiao Y, Freeman G . A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2. Clin Cancer Res. 2015; 21(10):2201-3. PMC: 4433776. DOI: 10.1158/1078-0432.CCR-14-2658. View

Quan H, Shan Z, Liu Z, Liu S, Yang L, Fang X . The repertoire of tumor-infiltrating lymphocytes within the microenvironment of oral squamous cell carcinoma reveals immune dysfunction. Cancer Immunol Immunother. 2020; 69(3):465-476. PMC: 11027813. DOI: 10.1007/s00262-020-02479-x. View

Chen X, Tan Y, Zhang N, He M, Zhou G . Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes. Pathol Res Pract. 2019; 215(6):152418. DOI: 10.1016/j.prp.2019.04.010. View

10.

Wirsing A, Ervik I, Seppola M, Uhlin-Hansen L, Steigen S, Hadler-Olsen E . Presence of high-endothelial venules correlates with a favorable immune microenvironment in oral squamous cell carcinoma. Mod Pathol. 2018; 31(6):910-922. DOI: 10.1038/s41379-018-0019-5. View

11.

Zandberg D, Strome S . The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol. 2014; 50(7):627-32. DOI: 10.1016/j.oraloncology.2014.04.003. View

12.

Song M, Park B, Uhm J . Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma. Int J Mol Sci. 2019; 20(6). PMC: 6470519. DOI: 10.3390/ijms20061326. View

13.

Okazaki T, Honjo T . PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007; 19(7):813-24. DOI: 10.1093/intimm/dxm057. View

14.

Schildberg F, Klein S, Freeman G, Sharpe A . Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity. 2016; 44(5):955-72. PMC: 4905708. DOI: 10.1016/j.immuni.2016.05.002. View

15.

Berghoff A, Ricken G, Widhalm G, Rajky O, Hainfellner J, Birner P . PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). Clin Neuropathol. 2013; 33(1):42-9. DOI: 10.5414/np300698. View

16.

Kouketsu A, Sato I, Oikawa M, Shimizu Y, Saito H, Takahashi T . Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients. J Craniomaxillofac Surg. 2018; 47(1):33-40. DOI: 10.1016/j.jcms.2017.04.013. View

17.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

18.

Ni L, Dong C . New B7 Family Checkpoints in Human Cancers. Mol Cancer Ther. 2017; 16(7):1203-1211. PMC: 5568666. DOI: 10.1158/1535-7163.MCT-16-0761. View

19.

Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J . Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003; 73(9):712-6. DOI: 10.1046/j.1445-2197.2003.02748.x. View

20.

Takakura H, Domae S, Ono T, Sasaki A . The Immunological Impact of Chemotherapy on the Tumor Microenvironment of Oral Squamous Cell Carcinoma. Acta Med Okayama. 2017; 71(3):219-226. DOI: 10.18926/AMO/55204. View